Inhibitory effect of recombinant IL-25 on the development of dextran sulfate sodium-induced experimental colitis in mice.
The role of interleukin 25 (IL-25) in a number of human diseases still has not been extensively studied, here we attempt to evaluate the role of recombinant IL-25 (rIL-25) in the development of dextran sulfate sodium (DSS)-induced experimental colitis. Acute colitis was induced in female C57BL/6 mice by oral administration of 2.5% DSS in drinking water ad libitum. At the same time as the start of DSS exposure, mice were injected intraperitoneally with 0.4 microg of rIL-25 or PBS. Then disease activity index (DAI), histological changes and survival rate were observed. The levels of IL-17, IL-23, and TGF-beta1 in colon tissues were determined by ELISA, and the production of IL-17 by CD4(+)/CD8(+) T cells was detected by intracellular flow cytometry. In contrast to the DSS treated mice, DSS + rIL-25 treated mice displayed a lower DAI, limited histological changes and prolonged survival. The levels of IL-23 and TGF-beta1 were significantly elevated in the DSS + rIL-25 treated mice compared to the DSS treated mice. There was no significant difference in the production of IL-17 in colon tissues and CD4(+)/CD8(+) T cells between the DSS + rIL-25 treated mice and DSS treated mice. Our findings suggest the role of IL-25 in inhibiting development and progression of acute colitis in DSS-induced mouse colitis model.
Mchenga
S S Salum
SS
Department of Immunology, College of Basic Medical Science, China Medical University, Shenyang, China.
Wang
Danan
D
Li
Cheng
C
Shan
Fengping
F
Lu
Changlong
C
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D003092:Colitis / Q000188:drug therapy* / Q000473:pathology*; D016264:Dextran Sulfate; D018450:Disease Progression; D005260:Female; D005434:Flow Cytometry; D020381:Interleukin-17 / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D053759:Interleukin-23 / Q000378:metabolism; D053208:Kaplan-Meier Estimate; D051379:Mice; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D053773:Transforming Growth Factor beta1 / Q000378:metabolism
D020381:Interleukin-17; D053759:Interleukin-23; D011994:Recombinant Proteins; D053773:Transforming Growth Factor beta1; D016264:Dextran Sulfate